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Pentavalent antimony complexes, such as sodium stibogluconate and sodium antimony gluconate (SAG), are still
the first choice for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis, or
kala-azar. Although the requirement of a somewhat functional immune system for the antileishmanial action of
antimony was reported previously, the cellular and molecular mechanism of action of SAG was not clear. Herein,
we show that SAG induces extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 phosphorylation through
phosphoinositide 3-kinase (PI3K), protein kinase C, and Ras activation and p38 mitogen-activated protein kinase
(MAPK) phosphorylation through PI3K and Akt activation. ERK-1 and ERK-2 activation results in an increase in
the production of reactive oxygen species (ROS) 3 to 6 h after SAG treatment, while p38 MAPK activation and
subsequent tumor necrosis factor alpha release result in the production of nitric oxide (NO) 24 h after SAG
treatment. Thus, this study has provided the first evidence that SAG treatment induces activation of some important
components of the intracellular signaling pathway, which results in an early wave of ROS-dependent parasite killing
and a stronger late wave of NO-dependent parasite killing. This opens up the possibility of this metalloid chelate
being used in the treatment of various diseases either alone or in combination with other drugs and vaccines.
Visceral leishmaniasis, caused by Leishmania donovani, is
fatal if left untreated. The pentavalent antimony (SbV) com-
pound urea stibamine first emerged as an effective chemother-
apeutic agent against Indian kala-azar (6). Although different
forms of pentavalent antimony complexes (chelates, i.e., SbV
chelated to an organic backbone), namely, sodium stibogluconate
(Pentostam) and meglumine antimoniate (Glucantime), are still
the first choice for treatment of leishmaniases (21, 42), their
mechanism of action is still largely unknown. Previous studies
indicated that sodium antimony gluconate (SAG) failed to act in
immunocompromised hosts, such as patients who are suffering
from AIDS or receiving immunosuppressive agents (17, 38) and
nude (36) and severe combined immunodeficient (SCID) mice
(15). Several studies have shown that endogenous interleukin-2
(IL-2) (34), IL-4 (1, 43), and IL-12 (41) influence the effectiveness
of chemotherapy with pentavalent antimony. These findings are
inclined to indicate the requirement of a somewhat functional
T-cell compartment for SAG action. Moreover, SAG has been
found to inhibit selective protein tyrosine phosphatases (Src ho-
mology 2 domain-containing tyrosine phosphatase 1 [SHP1] and
SHP2) in vitro and augment cytokine signaling and responses in
hematopoietic cell lines (46), suggesting the role of phosphatases
and possibly other signal transduction pathways in SAG-induced
control ofLeishmania infection. In addition, the dose of SAG that
kills the axenic amastigotes in vitro is 50 times higher than the
concentration of the drug required for killing the parasite within
macrophages (Ms) (23), suggesting host cell activation as an
integral component of SAG-induced antileishmanial effects.
Moreover, SAG synergizes with alpha interferon (IFN-) to ac-
tivate STAT1 to kill IFN--resistant human cancer cell lines, like
WM9 (melanoma), SW620 (colon carcinoma), U266 (multiple
myeloma), MDA231 (prostate cancer), etc., in vitro (56). These
studies indicate that this metalloid chelate might modulate a
number of signaling events. Therefore, we assessed whether SAG
modulates the signal transduction pathways in macrophages to
kill the intracellular parasites. Herein, we report for the first time
that SAG triggers activation of phosphoinositide 3-kinase (PI3K),
protein kinase C (PKC), and mitogen-activated protein kinases
(MAPKs) coupled with the activation of the microbicidal mech-
anism of M, which ultimately leads to the elimination of the
intracellular L. donovani parasites.
MATERIALS AND METHODS
Antibodies and other reagents. Anti--actin monoclonal antibody (MAb) was
purchased from Sigma (St. Louis, MO). Anti-tumor necrosis factor alpha
(TNF-) MAb and an Opt enzyme immunoassay kit for assay of TNF- were
obtained from BD Biosciences (San Diego, CA). Anti-PI3K and anti-phospho-
PI3K (p85) were obtained from Santa Cruz Biotech, Inc. All other antibodies
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(Abs) (anti-Akt, anti-phospho-Akt [Ser473], anti-PKC , anti-phospho-PKC
/II [Thr638/641], anti-Raf, anti-phospho-Raf [Ser338], anti-p38 MAPK, anti-
phospho-p38 MAPK [Thr180/Tyr182], anti-p42/44 MAPK, and anti-phospho-
extracellular signal-regulated kinase [ERK] [Thr202/Tyr204]), inhibitors (U0126
and SB203580), and LumiGlo reagents for chemiluminescence were obtained
from Cell Signaling (Beverly, MA). Fetal bovine serum (FBS) was obtained from
Invitrogen Corporation (Carlsbad, CA). Inhibitors (wortmannin, calphostin C,
and mevastatin), Giemsa stain, Bradford reagent, N-acetylcysteine (NAC), NG-
monomethyl-L-arginine acetate (L-NMMA), EDTA, EGTA, Tris base, N(1-
naphthyl)ethylenediaminedihydrochloride, sulfanilamide, sodium orthovanadate
(Na3VO4), Triton X-100, phenylmethylsulfonyl fluoride, leupeptin, aprotinin,
antipain, N-p-tosyl-phenylalanine chloromethyl ketone (TPCK), N-p-tosyl-L-
lysine chloromethyl ketone (TLCK), starch, penicillin, streptomycin, medium
199 (M199), RPMI 1640, and trypan blue were obtained from Sigma (St. Louis,
MO). 2,7-Dichloro dihydrofluorescein diacetate (DCFDA) was obtained from
Molecular Probes (Eugene, OR). Preservative-free sodium stibogluconate was
the kind gift of Albert David India, Ltd. (Calcutta, India).
Parasites, animals, and cell culture. Leishmania donovani MHOM/IN/1983/
AG83 (50) parasites were used during the course of this investigation. Amasti-
gotes obtained from spleens of infected hamsters were cultured in M199 con-
taining 20% (vol/vol) heat-inactivated FBS supplemented with 100 IU/ml of
penicillin and 100 g/ml of streptomycin at 22°C to obtain promastigotes (11).
Promastigotes were grown in fresh M199 containing 10% (vol/vol) heat-inacti-
vated FBS for 3 to 5 days at 22°C before further experimentation.
BALB/c and C57BL/6 (wild-type and inducible nitric oxide synthase-deficient
[iNOS/]) mice, originally obtained from Jackson Laboratories, Bar Harbor,
ME, and reared in the institute animal facilities, were used for experimental
purposes with prior approval of the animal ethics committee.
Ms were isolated from mice 36 to 48 h after injection (intraperitoneal) with
2% (wt/vol) hydrolyzed starch by peritoneal lavage with ice-cold phosphate-
buffered saline. Cells were washed and cultured for 18 to 24 h (for adherence) in
RPMI 1640 (supplemented with 100 IU/ml of penicillin and 100 g/ml of strep-
tomycin) containing 10% (vol/vol) heat-inactivated FBS (RPMI-FBS) at 37°C at
5% CO2 in air in tissue culture petri dishes of 65 mm in diameter (Tarson India
Ltd.), following which culture medium was washed off and fresh RPMI-FBS was
added. About 1  106 Ms were cultured in 1 ml of RPMI-FBS. In some
experiments, 5  105 Ms were maintained on 22-mm by 22-mm cover glass
placed in plastic petri dishes.
Infection of Ms and determination of intracellular parasite numbers. Dur-
ing the course of this study, Ms were infected with promastigotes at a M-to-
parasite ratio of 1:10 in RPMI-FBS, as described elsewhere (11). After 4 h of
incubation at 37°C at 5% CO2 in air, unbound parasites were washed off with
RPMI and Ms were then maintained in RPMI-FBS for 22 h at 37°C at 5% CO2
in air. Intracellular parasite numbers were enumerated in Giemsa-stained prep-
arations of samples, as described elsewhere (11, 51).
Treatments. At 22 h postinfection, the Ms were treated with SAG at a
concentration of 10 g/ml, because this is the highest attainable serum concen-
tration of the drug during chemotherapy of kala-azar patients (4, 46) and we have
also previously demonstrated the drug to be cytotoxic in vitro above 10 g/ml
(13). In some experiments, cells were treated with the PI3K inhibitor wortman-
nin (1 M) (22), the PKC inhibitor calphostin C (50 nM) (24), the Ras inhibitor
mevastatin (5 M) (20), the p38 MAPK inhibitor SB203580 (5 M) (47), the
MEK-1/MEK-2 inhibitor U0126 (1 M) (16), L-NMMA (0.4 mM) (18), or
anti-TNF- Ab (10 g/ml) for 1 h prior to SAG treatment (10 g/ml) or were
treated with NAC (5 mM) (49) along with SAG. The doses of inhibitors men-
tioned above were found to be nontoxic and were used by others previously (16,
18, 20, 22, 24, 47, 49). We also observed that wortmannin, calphostin C, mevas-
tatin, SB203580, U0126, L-NMMA, and TNF- Ab were not cytotoxic to Ms, as
evidenced by an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) assay and unaltered M morphology at the above-mentioned doses (data
not shown). NAC at the above-mentioned reported dose was found to be non-
toxic even after 18 h, as determined by trypan blue exclusion staining.
Measurement of ROS. To monitor the level of reactive oxygen species (ROS)
(including superoxide, hydrogen peroxide, and other reactive oxygen intermedi-
ates) produced within the cells, the cell-permeable, nonpolar, H2O2-sensitive
probe DCFDA was used (53). Extent of H2O2 generation was defined as ROS
generation for our convenience. Uninfected Ms and infected Ms (I-Ms),
untreated or treated with SAG for various durations, were pretreated in some
experiments with wortmannin, calphostin C, mevastatin, U0126, or SB203580 for
1 h or treated with NAC along with SAG. The cells were harvested in Hanks
balanced salt solution (HBSS). Finally, 1  106 cells were placed in 1 ml of
HBSS, pulsed with DCFDA (5 M) for 20 to 30 min at 37°C in the dark, and
then washed twice with HBSS; the relative fluorescence was measured by fluo-
rimetry with a fluorimeter (Hitachi) (excitation at 505 nm and emission at 525
nm at a slit size of 1 nm). For each experimental sample, fluorimetric measure-
ments were performed in triplicate and expressed as fluorescent intensity units/
106 cells.
Measurement of NO. Nitric oxide (NO) generation in response to SAG treat-
ment of Ms or I-Ms was monitored by Griess reaction as described previously
(18, 19). In some experiments, the cells were treated with wortmannin, calphostin
C, mevastatin, U0126, SB203580, anti-TNF-, or L-NMMA for 1 h prior to SAG
treatment. The amount of nitrite accumulated was calculated from a standard
curve constructed with different concentrations of sodium nitrite, and the con-
centration of nitrite accumulated was expressed as M nitrite.
Preparation of cell lysates and Western blot analysis. Uninfected Ms or
I-Ms, either untreated or treated with SAG for different durations, were har-
vested, resuspended in TEEM buffer (32), and rapidly freeze-thawed thrice and
passed through a 26-gauge needle (10 times) for lysis. The lysates were centri-
fuged (800  g for 10 min at 4°C), the supernatants were collected, and the
proteins were estimated using Bradford reagent. The supernatants were mixed
with Laemmli buffer, heated in a boiling water bath for 5 min, and cooled to
room temperature. About 20 g of protein was loaded in each lane of sodium
dodecyl sulfate-polyacrylamide gels, electrophoresed, and then transferred onto
polyvinylidene difluoride membrane. Immunoblotting was performed with ap-
propriately diluted specific primary Abs, and finally chemiluminescence was
performed with LumiGlo reagent as described by the manufacturer. Densito-
metric analyses were done using Quantity1 (Bio-Rad) software.
Assay of cytokines. Uninfected or MHOM/IN/1983/AG83-infected Ms (1 
106) were treated with SAG for different durations in a final culture volume of
200 l. The supernatants were collected after centrifugation. Then, TNF- was
assayed using an enzyme-linked immunosorbent assay kit according to the man-
ufacturer’s protocol.
Statistical analysis. Each experiment was performed three to five times and
results are expressed as means 	 standard errors of the means (SEM), or
Student’s t test for significance was performed and a P value of 
0.05 was
considered significant. Western blots show representative data from three inde-
pendent experiments.
RESULTS
SAG-induced generation of ROS and NO in macrophage
and control of intracellular parasites. Since ROS and NO are
the two major microbicidal molecules (2), we examined
whether the antileishmanial effects of SAG were dependent on
these two free radicals. It was observed that the amastigotes
grew until 24 h after infection in the SAG-untreated I-Ms,
whereas in SAG-treated I-Ms the amastigote count steadily
declined (Fig. 1A), suggesting an early control of the parasite
load by SAG.
Since pentavalent antimonial treatment in vitro induces
ROS generation in human polymorphonuclear cells (48), we
studied the ability of SAG to induce ROS in uninfected Ms
and I-Ms. We observed that ROS generation was enhanced
significantly (P 
 0.001) in uninfected Ms upon SAG treat-
ment. The peak was attained at 3 h, and the level decreased
gradually thereafter (Fig. 1B). Similarly, there was a slight
enhancement of NO generation with time in uninfected Ms
but this was significantly (P 
 0.001) enhanced upon SAG
treatment (Fig. 1C). When I-Ms were treated with SAG,
there was early ROS and late NO generation, which was es-
sentially comparable to observations with SAG-treated unin-
fected Ms (Fig. 1B and C). However, there was a slight right
shift of the peak of ROS generation, the cause of which is not
known (Fig. 1B). Interestingly, as with starch-elicited Ms,
SAG could induce both ROS and NO generation in resident
peritoneal Ms and could induce high levels of ROS genera-
tion in P388D1 cells (data not shown).
To ascertain that ROS is indeed involved in the early-hour
killing of L. donovani, I-Ms were treated with NAC, a potent
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scavenger of ROS, 1 h prior to SAG treatment; this inhibited
the SAG-mediated killing of intracellular L. donovani at 6 h
(i.e., when SAG-mediated ROS generation was highest and
NO generation was negligible in I-Ms) by more than 60%
(Fig. 2A). Similar data were also obtained with tocopherol at
this time point (unpublished data). For our subsequent exper-
iments concerning ROS generation, we have taken the 6-h
posttreatment time point because ROS generation peaked at
this point in I-Ms in response to SAG treatment (Fig. 1B).
Since a significant level of NO was produced at 24 h and 48 h
(Fig. 1C) in SAG-treated I-Ms, we assessed the intracellular
parasite numbers in the presence or absence of L-NMMA at
these time points. Significant (P 
 0.001) inhibition of SAG-
mediated parasite killing occurred in the presence of L-NMMA
at 24 h post-SAG treatment, the action being more pro-
nounced at the 48-h time point (Fig. 2A). The role of iNOS2
was demonstrated by the lack of an antileishmanial effect of
SAG in iNOS-deficient Ms at a later phase of infection in
vitro (Fig. 2B). It has been shown earlier that CD40-induced
expression of iNOS2 is mediated by p38 MAPK activation (31).
Therefore, it is quite possible that the SAG-induced NO gen-
eration is also dependent on signaling intermediates.
Inhibitors of PI3K, PKC, Ras, and ERKs strongly inhibited
SAG-induced ROS generation, while inhibitors of PI3K and
p38 MAPK strongly inhibited SAG-induced NO generation.
Since ROS generation is reported to involve Ras (54), PI3K
(14), PKC (55), and ERKs (14, 54), we tested whether different
inhibitors of these intermediates alter the SAG-induced ROS
production in Ms. We observed that treatment of I-Ms with
inhibitors of PI3K (i.e., wortmannin), PKC (i.e., calphostin C),
Ras (i.e., mevastatin), or MEK (i.e., U0126) prior to SAG
treatment strongly inhibited the SAG-induced ROS generation
(Fig. 3, top). Taking the SAG-induced increase in ROS gen-
eration over the untreated control value as 100%, the extents
of inhibition of ROS generation were 58.5% with wortman-
nin, 74.16% with calphostin C, 55% with mevastatin, and
71% with U0126. On the other hand, the inhibitor of p38
MAPK (i.e., SB203580) only marginally (16.6%) inhibited
the SAG-induced ROS generation. This study was carried out
at 6 h because maximum ROS generation was observed for
I-Ms at this time point.
The p38 MAPK has widely been reported to be involved in
NO generation (3, 25, 31), and activation of p38 MAPK is
reported to require the involvement of PI3K (25, 30, 52).
Therefore, we tested with inhibitors of PI3K and p38 MAPK to
determine whether SAG involves this pathway to induce NO
production in Ms. It was observed that treatment of I-Ms
with wortmannin or SB203580 prior to SAG treatment almost
completely inhibited the SAG-induced NO generation at 24 h
and also inhibited intracellular parasite killing by 94% or
99%, respectively (Fig. 3, bottom). On the contrary, pretreat-
ment with inhibitors of PKC, Ras, and ERKs had only minor
inhibitory effects (5%, 14.8%, and 18.9%, respectively)
on SAG-induced NO production. This study was also con-
ducted at the 48-h time point, and the results obtained were
essentially similar to those obtained at the 24-h time point.
However, the result for the 24-h time point has been presented
because the difference in numbers of intracellular L. donovani
parasites between untreated and SAG-treated Ms was max-
imal at this time point. Altogether, these data suggest that
FIG. 1. SAG-induced generation of ROS and NO in Ms and
killing of intracellular parasites. Uninfected Ms and Ms infected
with L. donovani (I-Ms) were either kept untreated or treated with
SAG for different durations. (A) Intracellular parasite numbers were
measured for I-Ms in the absence or presence of SAG. (B) ROS
generation was measured with DCFDA; uninfected Ms and I-Ms
showed significant increases in ROS generation at 3 h and 6 h post-
SAG treatment, respectively, compared with levels for corresponding
untreated controls (*, P 
 0.001). (C) Nitrite was measured using
Griess reagent in cell-free culture supernatants of SAG-treated unin-
fected Ms; I-Ms showed significant increase in nitrite generation
compared to untreated counterparts (*, P 
 0.001; **, P 
 0.005). All
results are presented as means 	 SEM of five independent experi-
ments.
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SAG results in activation of PI3K, PKC, Ras, and MEK-1/
MEK-2 for ROS generation and that it activates p38 MAPK
for NO generation.
SAG treatment induced phosphorylation of PI3K, PDK1,
Akt, PKC /II, Raf, ERKs, and p38 MAPK. After identi-
fying the signaling intermediates required for SAG-induced
ROS and NO generation, we examined the phosphorylation
status of PI3K, PKC, Raf, ERKs, p38 MAPK, and other
associated molecules, like phosphoinositide-dependent ki-
nase 1 (PDK1) and Akt, that are intermediates in the p42/44
FIG. 2. Effect of NAC (scavenger of ROS) and L-NMMA (com-
petitive inhibitor of iNOS) on SAG-mediated intracellular parasite
killing. (A) I-Ms cultured on cover glasses were either kept untreated
or treated with NAC or L-NMMA prior to SAG treatment. After
indicated time points, cover glasses were stained with Giemsa stain and
assessed for intracellular parasite number. Pretreatment with NAC
and L-NMMA significantly inhibited SAG-mediated parasite killing
(*, P
 0.005 for NAC; **, P
 0.001 for L-NMMA) compared to levels
for corresponding SAG-treated controls. Results are presented as
means 	 SEM of four independent experiments. (B) Peritoneal Ms
isolated from iNOS/ and wild-type C57BL/6 mice were cultured on
cover glasses, infected with L. donovani, and either kept untreated or
treated with SAG for 24 h and 48 h, following which their intracellular
parasite numbers were assessed. SAG-mediated intracellular L. dono-
vani killing was significantly inhibited in infected Ms of iNOS/
mice (*, P 
 0.005; **, P 
 0.001). Results are presented as means 	
SEM of three independent experiments.
FIG. 3. Effect of inhibitors of PI3K (wortmannin), PKC (calphostin
C), Ras (mevastatin), and ERK (U0126) on SAG-induced generation of
ROS and that of inhibitor of p38 MAPK (SB203580) on SAG-induced
generation of NO. I-Ms were treated () with wortmannin, calphostin
C, mevastatin, U0126, or SB203580 prior to SAG treatment. (Top) ROS
levels were measured after 6 h of SAG treatment, and corresponding
intracellular parasite numbers were also assessed. Pretreatment with wort-
mannin, calphostin C, mevastatin, or U0126 significantly inhibited SAG-
mediated ROS generation as well as parasite killing (P 
 0.005). (Bot-
tom) Nitrite levels in cell-free culture supernatant were estimated after
24 h of SAG treatment, and corresponding intracellular parasite numbers
were also assessed. Pretreatment with wortmannin or SB203580 signifi-
cantly inhibited SAG-mediated NO generation as well as parasite killing
(P 
 0.001). For both panels, numbers in parentheses show percentages
of inhibition of SAG-mediated intracellular parasite killing compared to
levels for respective SAG-treated controls. Results are presented as
means 	 SEM of five independent experiments. As mentioned in Mate-
rials and Methods, the inhibitors did not exhibit any cytotoxicity at the
doses used in this and subsequent experiments.
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MAPK and p38 MAPK activation pathways (26, 30, 52).
Since PKC  and  are known to be involved in the ERK
activation pathway (7, 8), we tested the phosphorylation of
PKC /II in this study.
It was observed that SAG treatment of I-Ms for only 30
min induced the phosphorylation of PI3K, PDK1, PKC
/II, Raf, and ERKs (Fig. 4). PI3K phosphorylation in-
creased gradually with an increase in duration of SAG treat-
ment up to 2 h and remained high even up to 24 h. The
extent of phosphorylation of PI3K following 2 h of SAG
treatment was 4-fold compared to that for the infected
control. Phosphorylations of PDK1 and PKC /II were
maximal at 30 min post-SAG treatment. The extents of
phosphorylation of PDK1 and PKC /II following 0.5 h of
SAG treatment were 3-fold and 2.5-fold, respectively,
compared to that for the infected control. Thereafter, the
phosphorylation level of PKC /II decreased gradually, but
the PDK1 phosphorylation was sustained (at an 2-fold-
higher level than that for the infected control, even up to
24 h). Interestingly, Raf phosphorylation, which increased
gradually from 30 min with an increase in duration of SAG
treatment, remained high even up to 2 h of treatment and
then decreased gradually. Strong phosphorylation of ERKs
was observed up to 2 h of SAG treatment; it decreased
FIG. 4. SAG treatment induces phosphorylation of PI3K, PDK1, Akt, PKC /II, Raf, ERK, and p38 MAPK. I-Ms were either kept untreated
or treated with SAG for different durations; cell lysates were prepared, run in 10% polyacrylamide gels, and immunoblotted with MAbs against
whole and phosphorylated forms (labeled Phospho or P) of PI3K, PKC /II (phosphorylated form of /II and whole  only), PDK1, Raf,
ERK-1/ERK-2, p38 MAPK, and Akt, with -actin as an internal control. The phosphorylation status of each of the above molecules was expressed
as the densitometric ratio of the phosphorylated form versus the expression control. Representative data of three similar experiments are
presented. AG83, MHOM/IN/1983/AG83.
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gradually thereafter. The extents of phosphorylation of ERK-1
and ERK-2 following 1 h and 2 h of SAG treatment were
1.5-fold and 2-fold, respectively, compared to that for the
infected control. Phosphorylation of Akt was very weak at 30
min following SAG treatment but increased gradually and
reached the peak at about 6 h posttreatment, i.e., when the
SAG-induced phosphorylation of PKC /II became very
weak. The extent of phosphorylation of Akt following 6 h of
SAG treatment was 2-fold compared to that for the infected
control. Phosphorylation of p38 MAPK was evident only fol-
lowing 1 h of SAG treatment; it gradually increased up to 6 h
and then decreased slightly but persisted even up to 24 h
post-SAG treatment (Fig. 4). The peak of phosphorylation of
p38 MAPK was observed to occur following 6 h of SAG treat-
ment, and the extent was 4.5-fold compared to that for the
infected control.
To test the probable pathway for SAG-induced phosphory-
lation of ERKs and p38 MAPK in I-Ms, Western blot exper-
iments were performed with inhibitors of PI3K, PKC, and Ras.
We observed that pretreatment with wortmannin completely
abrogated SAG-induced PDK1 and PKC /II phosphoryla-
tion at 30 min and almost completely inhibited the SAG-in-
duced phosphorylations of Raf and ERKs at 1 h (Fig. 5). On
the other hand, wortmannin pretreatment also completely ab-
rogated SAG-induced phosphorylation of Akt and almost com-
pletely inhibited that of p38 MAPK at 6 h (Fig. 5). Further,
pretreatment with calphostin C or mevastatin strongly inhib-
ited SAG-induced phosphorylations of Raf and ERKs at 1 h
but not that of Akt or p38 MAPK at 6 h.
SAG treatment triggered TNF- production through partic-
ipation of p38 MAPK. Activation of p38 MAPK is well re-
ported to trigger production of TNF- (29), which is known to
induce iNOS2 expression and NO generation (29). These stud-
ies prompted us to investigate the involvement of TNF- in
FIG. 5. PI3K phosphorylation due to SAG treatment induces phosphorylation of PDK1, PKC /II, Raf, and ERK-1/ERK-2 as well as that of
Akt and p38 MAPK. I-Ms were treated with an inhibitor of PI3K (wortmannin), PKC (calphostin C), or Ras (mevastatin) for 1 h prior to SAG
treatment, and the phosphorylation status of PDK1 and PKC /II at 30 min of SAG treatment, Raf and ERK at 1 h of SAG treatment, and Akt
and p38 MAPK at 6 h of SAG treatment (SAG-induced phosphorylation status of each of the above-mentioned signaling molecules was maximal
at these time points) was determined by immunoblotting. Phosphorylation status of each of the above-mentioned molecules was expressed as the
densitometric ratio of the phosphorylated form (labeled Phospho or P) versus the internal control (-actin). Representative data of three similar
experiments are presented here.
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the SAG-mediated NO generation due to activation of p38
MAPK.
SAG treatment of I-Ms induced TNF- production (Fig. 6A),
and this could be inhibited almost completely by pretreatment
with wortmannin or SB203580. On the contrary, pretreatment
with an inhibitor of PKC, Ras, or ERKs failed to show any
significant inhibition (extent of inhibition was7.1%,14.6%,
or 12%, respectively) (Fig. 6A). We then investigated
whether the SAG-induced NO production in I-Ms was me-
diated by TNF-. It was observed that incubation of I-Ms
with anti-TNF- neutralizing Ab strongly suppressed SAG-
induced NO production after 24 h and completely abrogated it
FIG. 6. SAG induces TNF- production from L. donovani-infected Ms through participation of PI3K and p38 MAPK. (A) I-Ms were either
kept untreated () or treated () with wortmannin, calphostin C, mevastatin, U0126, or SB203580 prior to SAG treatment; cell-free culture
supernatants were collected after 18 h and assayed for TNF- by sandwich enzyme-linked immunosorbent assay. Pretreatment with wortmannin
or SB203580 significantly inhibited SAG-mediated TNF- generation (**, P 
 0.001). (B) In some experiments, I-M was either kept untreated
or treated with SAG in the presence or absence of neutralizing anti-TNF- MAb, and resulting levels of nitrite accumulated in cell-free culture
supernatants after 24 h of SAG treatment were measured. (C) Corresponding intracellular parasite numbers were also assessed. Neutralization of
TNF- significantly inhibited SAG-mediated NO generation (P 
 0.005) as well as intracellular L. donovani killing (P 
 0.005 at 24 h). Results
presented are means 	 SEM of four independent experiments.
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after 48 h (Fig. 6B). Furthermore, incubation of I-Ms with
anti-TNF- neutralizing Ab also inhibited SAG-induced killing
of intracellular L. donovani parasites partially (60.8%), but
significantly (P 
 0.01), at 24 h and completely after 48 h (P 

0.005) (Fig. 6C).
DISCUSSION
The present study has provided the first insight into the
involvement of signaling intermediates, namely, PI3K, PKC,
and MAPKs, in SAG-mediated generation of the leishmani-
cidal molecules (ROS and NO). Our results show that SAG
treatment alone induced both ROS and NO in murine Ms
and induced two waves of killing of L. donovani amastigotes.
The first phase of killing (i.e., at an early time point, around 6 h
posttreatment) was due to induction of ROS, as evident from
the sensitivity to tocopherol (data not shown) or NAC, while
the second wave of killing (i.e., at later time points, 24 h and
48 h) was mediated by NO generation, as evident from the
sensitivity to L-NMMA and failure of SAG to inhibit killing of
intracellular L. donovani parasite replication in peritoneal
Ms from iNOS/ C57BL/6 mice at 24 h posttreatment. Both
ROS and NO are known to be involved in parasite killing in the
early stage of leishmanial infection in mice, whereas NO alone
is involved in the late phase (39).
Since the SAG-induced phosphorylation of PKC /II,
which occurred by 30 min posttreatment, was observed to be
inhibited by wortmannin pretreatment, it is possible that SAG
treatment resulted in rapid phosphorylation of PI3K, which is
a well-known activator of PDK1 (9, 27) that in turn activates
several PKC isotypes (9, 27). Inasmuch as wortmannin, cal-
phostin C, and mevastatin inhibited the SAG-induced Raf
phosphorylation as late as 1 h, our observations present a new
mode of Raf activation which is very different from receptor
activation-mediated Raf activation and recruitment to the
membrane. Our results also suggest that SAG-induced activa-
tion of the PI3K-PKC-Ras/Raf pathway triggered ERK phos-
phorylation. Pretreatment of I-M with any of these inhibitors
or U0126 resulted in significant inhibition (P 
 0.01 for wort-
mannin and mevastatin and P 
 0.005 for calphostin C and
U0126) of SAG-mediated ROS generation, suggesting that
SAG activates the PI3K-PKC-Ras-ERK pathway and thereby
triggers ROS generation.
On the other hand, inhibition of PI3K or p38 MAPK
strongly abrogated SAG-mediated NO production in I-Ms as
well as parasite killing at 24 h following SAG treatment. This
suggested that NO production and subsequent parasite killing
in response to SAG treatment involved mainly PI3K and p38
MAPK. The PI3K-Akt-p38 MAPK pathway (25) was shown to
be involved in NO generation (25, 26). Activation of PKC
inhibits PI3K-mediated activation of Akt (33). In our study it
has also been observed that although Akt was phosphorylated
1 h following SAG treatment, the level reached a peak at 6 h
posttreatment, when phosphorylation of PKC /II was very
low. This phosphorylation could be inhibited by wortmannin
pretreatment, confirming that SAG-induced prolonged activa-
tion of PI3K resulted in Akt phosphorylation. The activation of
the PI3K-Akt pathway by SAG seemed to trigger phosphory-
lation of p38 MAPK that was almost completely abrogated by
wortmannin pretreatment. The PKC-Ras pathway played a
minimal role in SAG-induced p38 MAPK phosphorylation, as
it was insensitive to pretreatment with calphostin C or mevas-
tatin.
L. donovani infection has been reported to increase protein
tyrosine phosphatase activity, mainly that of type SHP1 (5,
44–46), which might contribute to dysregulation of protein
tyrosine kinase-dependent signaling events and M deactiva-
tion (44). SHP1 might directly dephosphorylate ERKs (45) and
regulate activation of other important signaling molecules, like
PI3K (12). Thus, inhibition of SHP1 by SAG might indirectly
favor the tyrosine phosphorylation of PI3K and might thereby
help in activating both the PI3K–PKC–Ras/Raf–ERK-1/ERK-2
pathway for ROS generation and the PI3K-Akt-p38 MAPK path-
way leading to NO generation.
The p38 MAPK has been shown to induce TNF- produc-
tion (29), which in turn induces iNOS2 expression and subse-
quent NO generation (29), as suggested by the inhibition of
NO generation and parasite killing by treatment with anti-
TNF- neutralizing Ab. The SAG-mediated TNF- generation
could be inhibited by wortmannin or SB203580 pretreatment,
indicating that SAG-induced activation of the PI3K-p38 MAPK
pathway not only activates NO-mediated parasite control but also
reinforces the mechanism by triggering endogenous TNF- that
controls the parasite in an autocrine manner. Indeed, the SAG-
induced antileishmanial activity is reduced in TNF- knockout
mice (35). In addition, since SAG up-regulates IFN- receptors
in both uninfected and L. donovani-infected THP-1 cells, as
well as in monocytes derived from kala-azar patients treated
with SAG (13), it is quite possible that SAG influences the
host’s antileishmanial defense by altering IFN- responsive-
ness. Indeed, SAG fails to act in IFN- knockout mice (40),
and in the case of chronic, nonhealing murine cutaneous leish-
maniasis, treatment with SAG plus IFN- induces much higher
levels of iNOS2 transcripts in footpad tissues than SAG or
IFN- alone (28). We have also observed that SAG and IFN-
synergize to produce high levels of NO in Ms (unpublished
data). A combination of SAG and IFN- is also known to be
therapeutically much more effective than SAG alone in the
treatment of visceral leishmaniasis (37). We have further ob-
served that SAG triggers production of IL-12 in both unin-
fected Ms and I-Ms (unpublished data). IL-12 is known to
induce Th cells to produce IFN-, which in turn activates Ms
to produce TNF- and, subsequently, NO. This might explain
the failure of SAG to act in IL-12 knockout mice, as reported
in earlier studies (41). Furthermore, an earlier study showed
that SAG treatment of infected mice imparted resistance to
reinfection whereas SAG treatment prior to infection imparted
partial resistance to L. donovani infection (10). All of these
results may explain the requirement of T cells for the activity of
SAG in vivo (36). Interestingly, neither sodium gluconate (i.e.,
the organic backbone of SAG) nor inorganic SbV (SbCl5)
could induce significant levels of ROS or NO generation and
parasite killing in I-Ms, while SbCl5 (at 10 g Sb
V equivalent)
proved to be highly cytotoxic (unpublished data), suggesting
that neither the backbone nor the metalloid alone has the
immunomodulatory effect shown by SAG (an organic chelate
of SbV). Therefore, the use of SAG in combination therapy
(either with other drugs or possibly with vaccines) may prove
beneficial. Moreover, our preliminary observations indicate that
resistance to antimonials occurred mainly due to overexpression
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of MRP1 on the host cell surface and consequent nonretention of
antimony by host cells harboring antimony-resistant strains of L.
donovani (unpublished observation), suggesting that the use of
suitable resistance-modifying agents might sensitize Sb-resistant
cases to SAG treatment. Further studies in this direction are
being pursued.
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